MENS (Jyong Biotech Ltd.) stock: $2.06, $156.6M market cap, $1.2M cash, $157.5M EV, $151.1M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Share price
$2.06
Market cap
$156.6M
Cash
$1.2M
Enterprise value
$157.5M
Balance sheet
Cash
$1.2M
Debt
$2.1M
Net cash
-$0.9M
Enterprise value
$157.5M
Basic shares
76.0M shares
Fully diluted shares
73.4M shares
Fully diluted market cap
$151.1M
Cash per share
$0.02
Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.
Price history
Loading MENS daily closes…
Loading price history…
Pipeline assets
Botreso
Phase 3 · Active
Indications
BPH/LUTS(Phase 3)
Prostate cancer prevention(Stage not disclosed)
Status note Core drug candidate for BPH/LUTS; four Phase III trials conducted with API-1 (two pivotal, two open-label extensions, U.S. and Taiwan). FDA raised concerns about the U.S. pivotal trial and reproducibility of the Taiwan study; company plans an additional Phase III (MCS-2-US-b) with API-2, contingent on FDA acceptance of API-1/API-2 comparability and CMC documentation.
PCP
Phase 2 · Active
Indications
not disclosed(Phase 2)
Status note Key drug candidate; Phases I and II studies conducted with API-1. If API-2 is not shown comparable to API-1, Phase I/II studies would need repeating with API-2.
IC
Stage not disclosed · Active
Indications
not disclosed(Stage not disclosed)
Status note Named as a key drug candidate; no target, modality, indication, or stage detail disclosed in excerpts.
Per-asset detail extracted from the 20-F filed 2026-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.